LoginMy Member Benefitsarchivesresearchyour teamabout usFAQLog out
×
Share
Access Your Profit Alerts

biotech penny stocks

Article Index

Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double

By , Associate Editor, Money Morning • @DavidGZeiler -

Usually the best stocks to buy have not already tripled in value within the past six months.

But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).

This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.

Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.

The crazy thing is, Intercept Pharma could actually double from here...

The Secret to Making Money from Bioscience's "Scariest Event"

By , Biotech Investing Specialist, Money Morning -

In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.

Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

Perhaps the least  understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

But they're also among the most powerful.

Here's what I mean, and how to play them profitably... Full Story

How to Spot Biotech Shares with “Blockbuster” Potential

By , Biotech Investing Specialist, Money Morning -

The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

And this is how you find them... Full Story

Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine”

By , Associate Editor, Money Morning • @KyleAndersonMM -

One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.

When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.

That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…

Finding the Blockbuster That Will Make You Rich

By , Biotech Investing Specialist, Money Morning -

In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.

It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.

So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.

There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search...

Full Story

Double Your Money with Our "High-Tech GPS"

By , Defense + Tech Specialist, Money Morning • @Robinson_STI -

Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.

And that means they have no retirement.

From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.

And I knew there was one avenue to travel - the high-tech highway.

So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.

Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.

So let's get started...

Three Bioscience Breakthroughs You Can't Afford to Miss

By , Biotech Investing Specialist, Money Morning -

You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline.

One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones - in other words, it plays with the basic building blocks of life as if they were Lego pieces!

Sangamo is currently using ZFP technology to find cures for some of the most intractable - and often un-druggable - diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few.

And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world - providing it with a great revenue stream.

As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money.

The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after.

With that in mind, here are a few exciting new technologies to keep an eye on... Full Story

Penny Stocks to Watch

By , Contributing Writer, Money Morning -

Top 10 Penny Stocks this year

The recent spate of uninspiring data, from unemployment to retail sales, has been blamed on the unrelenting cold and snowy winter. But one group that hasn't been affected, and isn't using the convenient "bad weather" excuse, is this list of penny stocks to watch now.

This week brought huge gains from several low-priced stocks across all sectors:

Here are four penny stocks to watch now.

Investing in Tech: We Sure Hope You Own These Three "Wealth Building Blocks"

By , Defense + Tech Specialist, Money Morning • @Robinson_STI -

I get a lot of questions from you folks here at the Strategic Tech Investor.

And the single most frequently asked query is this one:

"Michael, what's the best way to get started as a tech investor?"

I'll grant you: As questions go, that's probably the most basic one that you'll find.

To continue reading, please click here...

Cadence Pharmaceuticals (Nasdaq: CADX) Stock Climbs 26% in Latest Biotech Deal

By , Contributing Writer, Money Morning -

What a year so far for biotech stock profits...

Another consolidation in the active biotech sector came Tuesday when Cadence Pharmaceuticals Inc. (Nasdaq: CADX) agreed to be acquired by Mallinckrodt plc (NYSE: MNK) in a $1.3 billion deal. The move sent CADX up 26%.

Under terms of the deal, Dublin, Ireland-based Mallinckrodt will pay $14 in cash for each share of San Diego, Calif.-headquartered Cadence. That's a 26% premium to Monday's closing price and a 32% premium to the stock's average 30-day trading price.

To continue reading, please click here...

The Best Biotech Takeover Targets for 2014

By , Associate Editor, Money Morning • @KyleAndersonMM -

This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.

The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.

To continue reading, please click here...

Today's Markets
DJIA -623.34 (-2.37%) 25,628.90
NASDAQ -239.62 (-3.00%) 7,751.77
S&P -75.84 (-2.59%) 2,847.11